Equities research analysts expect Synlogic Inc (NASDAQ:SYBX) to announce earnings per share of ($0.44) for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Synlogic’s earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.60). Synlogic posted earnings of ($0.47) per share in the same quarter last year, which indicates a positive year over year growth rate of 6.4%. The firm is scheduled to report its next earnings results on Tuesday, March 10th.

On average, analysts expect that Synlogic will report full year earnings of ($1.80) per share for the current year, with EPS estimates ranging from ($1.96) to ($1.73). For the next year, analysts anticipate that the business will report earnings of ($1.69) per share, with EPS estimates ranging from ($2.09) to ($1.17). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that that provide coverage for Synlogic.

Synlogic (NASDAQ:SYBX) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.46 million. Synlogic had a negative return on equity of 34.49% and a negative net margin of 4,574.82%.

A number of equities analysts have recently commented on the company. Piper Jaffray Companies restated an “overweight” rating and issued a $7.00 price objective (down from $10.00) on shares of Synlogic in a report on Wednesday, November 13th. Citigroup downgraded Synlogic from a “buy” rating to a “sell” rating and dropped their target price for the company from $20.00 to $2.00 in a report on Wednesday, August 21st. Chardan Capital reiterated a “buy” rating on shares of Synlogic in a report on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Synlogic in a report on Wednesday. Finally, Zacks Investment Research upgraded Synlogic from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a report on Saturday, November 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the stock. Synlogic has an average rating of “Buy” and an average target price of $13.69.

Shares of Synlogic stock traded down $0.32 during trading hours on Friday, reaching $2.38. The stock had a trading volume of 538,521 shares, compared to its average volume of 527,126. The firm has a 50 day simple moving average of $2.23 and a two-hundred day simple moving average of $4.46. The firm has a market capitalization of $90.74 million, a price-to-earnings ratio of -1.17 and a beta of 2.54. The company has a current ratio of 12.70, a quick ratio of 12.70 and a debt-to-equity ratio of 0.14. Synlogic has a 1 year low of $1.91 and a 1 year high of $11.43.

Large investors have recently made changes to their positions in the stock. Flagship Harbor Advisors LLC purchased a new stake in shares of Synlogic during the 3rd quarter valued at about $34,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Synlogic during the 2nd quarter valued at about $195,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Synlogic by 11.1% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 3,708 shares during the period. Northern Trust Corp raised its holdings in shares of Synlogic by 17.1% during the 2nd quarter. Northern Trust Corp now owns 201,613 shares of the biotechnology company’s stock valued at $1,835,000 after buying an additional 29,401 shares during the period. Finally, State Street Corp raised its holdings in shares of Synlogic by 12.9% during the 3rd quarter. State Street Corp now owns 303,424 shares of the biotechnology company’s stock valued at $695,000 after buying an additional 34,552 shares during the period. Institutional investors and hedge funds own 61.00% of the company’s stock.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Featured Article: Why do commodities matter?

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.